Page last updated: 2024-11-13
pterodontic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pterodontic acid: anti-bacterial from Laggera pterodonta; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Laggera | genus | [no description available] | Asteraceae | A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 91895390 |
MeSH ID | M0537220 |
Synonyms (9)
Synonym |
---|
pterodontic acid |
185845-89-0 |
eudesmane-5,12-dien-13-oic acid |
AKOS032962138 |
2-[(2r,4ar,8s)-4a,8-dimethyl-3,4,5,6,7,8-hexahydro-2h-naphthalen-2-yl]prop-2-enoic acid |
pterodonticacid |
FS-10511 |
CS-0017113 |
HY-N1564 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.20) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (20.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |